In view of the current discussions on “plausibility”, in particular in the areas of chemistry and life sciences and as background for the upcoming EPO Enlarged Board of Appeal decision G 2/21 we “reload” an earlier article by our partner Holger Tostmann that was first published in the American Chemical Society’s Medicinal Chemistry Letters (ACS Med. Chem. Lett. 2015, 6, 364−366).
